The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients

AIDS Research and Human Retroviruses

Volumn 15, Issue 6, 1999, Pages 551-559

  Adams, Gregor B ^a   Pym, Alexander S ^a   Poznansky, Mark C ^b   McClure, Myra O ^a   Weber, Jonathan N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CD34 ANTIGEN; COTRIMOXAZOLE; DAPSONE; FAMCICLOVIR; GRISEOFULVIN; INDINAVIR; PENTAMIDINE; PYRIMETHAMINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CLINICAL ARTICLE; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; STEM CELL; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD34; CELLS, CULTURED; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MIDDLE AGED; RITONAVIR; SAQUINAVIR;

EID: 0033541467     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311079     Document Type: Article

References (27)

1. Lane HC and Fauci AS: Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 1985; 3:477-500.
2. Costello C: Haematological abnormalities in human immunodeficiency virus (HIV) disease. J Clin Pathol 1988;41:711-715.
3. Sun NCJ, Shapshak P, Lachant NA, Hsu M-Y, Sieger L, Schmid P, Beall G, and Imagawa DT: Bone marrow examination in patients with AIDS and AIDS-related complex (ARC). Am J Clin Pathol 1989;92:589-594.
4. Moses A, Nelson J, and Bagby GC Jr: The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998;91: 1479-1495.
5. Johnson M, Caiazzo T, Molina J-M, Donahue R, and Groopman J: Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol 1988;70:137-141.
6. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
7. Hermans P: Haematopoietic growth factors as supportive therapy in HIV-infected patients. AIDS 1995;9(Suppl. 2):S9-S14.
8. Browne MJ, Mayer KH, Chafee SBD, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denman SL, Dunkle LM, Kaul S, McLaren C, Skowron G, Kouttab NM, Kennedy TA, Weitberg AB, and Curt GA: 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. J Infect Dis 1993;167:21-29.
9. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, and Weber JN: Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-955.
10. Lambert JS, Seidlin M, Valentine FT, Reichman RC, and Dolin R: Didanosine: Long-term follow-up of patients in a phase 1 study. Clin Infect Dis 1993;16(Suppl. 1):S40-S45.
11. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, and Ho DD: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-1539.
12. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, and Drusano GL: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-492.
13. van Leeuwen R, Katlama C, Kitchen V, Boucher CAB, Tubiana R, McBride M, Ingrand D, Weber J, Hill A, McDade H, and Danner SV: Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase I/II study. J Infect Dis 1994;171:1166-1171.
14. Schacter LP, Rozencweig M, Beltangady M, Allan JD, Canetta R, Cooley TP, Dolin R, Kelley S, Lambert J, Liebman HA, Messina M, Nicaise C, Seidlin M, Valentine FT, Yarchoan R, and Smaldone LF: Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 1992;80:2969-2976.
15. Tozzi V, Narcisco P, Sebastiani G, Frigiotti D, and D'Amato C: Effects of indinavir treatment on platelet and neutrophil counts in patients with advanced HIV disease. AIDS 1997;11:1067-1068. [Letter]
16. Skowron G: Biologic effects and safety of stavudine: Overview of phase I and II clinical trials. J Infect Dis 1995;171(Suppl. 2): S113-S117.
17. + progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996;88:3329-3335.
18. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89:2259-2267.
19. Kearns K, Bahner I, Bauer G, Wei S-F, Valdez P, Wheeler S, Woods L, Miller R, Casciato D, Galpin J, Church J, and Kohn DB: Suitability of bone marrow from HIV-1-infected donors for retrovirus-mediated gene transfer. Hum Gene Ther 1997;8:301-311.
20. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
21. + repertoire during antiviral therapy. Nature Med 1998;4:215-221.
22. Pakker NG, Notermans DW, de Boer RJ, Roos MTL, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, and Schellekens PTA: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998;4:208-214.
23. Withers-Ward ES, Amado RG, Koka PS, Jamieson BD, Kaplan AH, Chen ISY, and Zack JA: Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nature Med 1997;3:1102-1109.
24. + progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86:1749-1756.
25. Roederer M: Getting to the HAART of T cell dynamics. Nature Med 1998;4:145-146.
26. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, and Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95: 2061-2066.
27. Najean Y and Rain J-D: The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med 1994;123:415-420.